EC-17 | CAS#583037-91-6 | tumor-specific fluorescent agent

MedKoo Cat#: 597300 | Name: EC-17 free acid

Description:

WARNING: This product is for research use only, not for human or veterinary use.

EC17, also known as Folate-FITC, is an FITC conjugated folic acid. It also acts as a FRα-targeting agent that fluoresces at 500nm. EC17 is conjugate consisting of fluorescein isothiocyanate (FITC) conjugated with folate with potential antineoplastic activity. Folate-FITC binds to folate receptors, which are overexpressed on the surfaces of many cancer cells including kidney and ovarian cancer cells. Once bound to the cancer cell through the folate moiety of the conjugate, curculating anti-fluorescein antibodies.may recognize and bind to the FITC moiety, resulting in antibody-dependent cellular cytotoxicity.

Chemical Structure

EC-17 free acid

CAS#583037-91-6 (free acid)

Theoretical Analysis

MedKoo Cat#: 597300

Name: EC-17 free acid

CAS#: 583037-91-6 (free acid)

Chemical Formula: C42H36N10O10S

Exact Mass: 872.2337

Molecular Weight: 872.87

Elemental Analysis: C, 57.79; H, 4.16; N, 16.05; O, 18.33; S, 3.67

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

910661-33-5 (sodium) 583037-91-6 (free acid)

Synonym

EC17; EC-17; EC 17; Folate-FTIC; FTIC-Folate;

IUPAC/Chemical Name

N2-(4-(((2-amino-4-oxo-4,8-dihydropteridin-6-yl)methyl)amino)benzoyl)-N5-(2-(3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-yl)thioureido)ethyl)-L-glutamine

InChi Key

LMEBZGHLPGBLSU-PMERELPUSA-N

InChi Code

InChI=1S/C42H36N10O10S/c43-40-51-35-34(37(57)52-40)48-23(19-47-35)18-46-21-3-1-20(2-4-21)36(56)50-30(38(58)59)11-12-33(55)44-13-14-45-41(63)49-22-5-8-27-26(15-22)39(60)62-42(27)28-9-6-24(53)16-31(28)61-32-17-25(54)7-10-29(32)42/h1-10,15-17,19,30,46,53-54H,11-14,18H2,(H,44,55)(H,50,56)(H,58,59)(H2,45,49,63)(H3,43,47,51,52,57)/t30-/m0/s1

SMILES Code

O=C1OC2(C=3C1=CC(NC(NCCNC(CC[C@H](NC(=O)C4=CC=C(NCC=5N=C6C(NC5)=NC(N)=NC6=O)C=C4)C(O)=O)=O)=S)=CC3)C=7C(OC=8C2=CC=C(O)C8)=CC(O)=CC7

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 872.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kikuchi A, Yanase T, Sasagawa M, Honma S. The role of para-aortic lymphadenectomy in stage IIIC endometrial cancer: A single-institute study. J Obstet Gynaecol. 2017 May;37(4):510-513. doi: 10.1080/01443615.2017.1281894. Epub 2017 Mar 2. PubMed PMID: 28421906. 2: Eyles JP, Hunter DJ, Meneses SRF, Collins NJ, Dobson F, Lucas BR, Mills K. Instruments assessing attitudes toward or capability regarding self-management of osteoarthritis: a systematic review of measurement properties. Osteoarthritis Cartilage. 2017 Aug;25(8):1210-1222. doi: 10.1016/j.joca.2017.02.802. Epub 2017 Mar 3. Review. PubMed PMID: 28263899. 3: Zinellu A, Sotgia S, Scanu B, Arru D, Cossu A, Posadino AM, Giordo R, Mangoni AA, Pintus G, Carru C. N- and S-homocysteinylation reduce the binding of human serum albumin to catechins. Eur J Nutr. 2017 Mar;56(2):785-791. doi: 10.1007/s00394-015-1125-5. Epub 2015 Dec 10. PubMed PMID: 26658763. 4: Prudent M, Tissot JD, Lion N. In vitro assays and clinical trials in red blood cell aging: Lost in translation. Transfus Apher Sci. 2015 Jun;52(3):270-6. doi: 10.1016/j.transci.2015.04.006. Epub 2015 Apr 16. Review. PubMed PMID: 25982219. 5: Takao K, Ishikawa R, Sugita Y. Synthesis and biological evaluation of 3-styrylchromone derivatives as free radical scavengers and α-glucosidase inhibitors. Chem Pharm Bull (Tokyo). 2014;62(8):810-5. PubMed PMID: 25087634. 6: Weenink JW, Braspenning J, Wensing M. Patient reported outcome measures (PROMs) in primary care: an observational pilot study of seven generic instruments. BMC Fam Pract. 2014 May 6;15:88. doi: 10.1186/1471-2296-15-88. PubMed PMID: 24884544; PubMed Central PMCID: PMC4029823. 7: Głowacka IE, Balzarini J, Wróblewski AE. The synthesis, antiviral, cytostatic and cytotoxic evaluation of a new series of acyclonucleotide analogues with a 1,2,3-triazole linker. Eur J Med Chem. 2013;70:703-22. doi: 10.1016/j.ejmech.2013.10.057. Epub 2013 Oct 30. PubMed PMID: 24219992. 8: Hamnes B, Mowinckel P, Kjeken I, Hagen KB. Effects of a one week multidisciplinary inpatient self-management programme for patients with fibromyalgia: a randomised controlled trial. BMC Musculoskelet Disord. 2012 Sep 26;13:189. doi: 10.1186/1471-2474-13-189. PubMed PMID: 23013162; PubMed Central PMCID: PMC3551734. 9: ten Klooster PM, Taal E, Siemons L, Oostveen JC, Harmsen EJ, Tugwell PS, Rader T, Lyddiatt A, van de Laar MA. Translation and validation of the Dutch version of the Effective Consumer Scale (EC-17). Qual Life Res. 2013 Mar;22(2):423-9. doi: 10.1007/s11136-012-0162-2. Epub 2012 Mar 28. PubMed PMID: 22453645; PubMed Central PMCID: PMC3576564. 10: Bremander A, Wikström I, Larsson I, Bengtsson M, Hagel S, Strömbeck B. Cultural adaptation, validity, reliability and responsiveness of the Swedish version of the effective musculoskeletal consumer scale (EC-17). Musculoskeletal Care. 2012 Mar;10(1):43-50. doi: 10.1002/msc.1006. Epub 2012 Feb 2. PubMed PMID: 22302732. 11: Rader T, Ueffing E, Garcia-Elorrio E, Idzerda L, Ciapponi A, Irazola V, Welch V, Lyddiatt A, Shea B, Newman S, Osborne R, Tugwell PS. Influencing health equity: role of the effective consumer scale in measuring skills and abilities in a middle income country. J Rheumatol. 2011 Aug;38(8):1798-802. doi: 10.3899/jrheum.110407. PubMed PMID: 21807803. 12: Palavra F, Gens H, Fernandes C, Pombo H, Gonçalves G. [Healthcare associated infection: emerging problem in a neurology department]. Acta Med Port. 2010 Jul-Aug;23(4):613-24. Epub 2010 Jul 30. Portuguese. PubMed PMID: 20687989. 13: Teixeira C, Teixeira TM, Brodt SF, Oliveira RP, Dexheimer Neto FL, Roehrig C, Oliveira ES. Appropriate medical professionals communication reduces intensive care unit mortality. Rev Bras Ter Intensiva. 2010 Jun;22(2):112-7. English, Portuguese. PubMed PMID: 25303751. 14: Hamnes B, Garratt A, Kjeken I, Kristjansson E, Hagen KB. Translation, data quality, reliability, validity and responsiveness of the Norwegian version of the Effective Musculoskeletal Consumer Scale (EC-17). BMC Musculoskelet Disord. 2010 Jan 29;11:21. doi: 10.1186/1471-2474-11-21. PubMed PMID: 20113488; PubMed Central PMCID: PMC2828423. 15: Santesso N, Rader T, Wells GA, O'Connor AM, Brooks PM, Driedger M, Gallois C, Kristjansson E, Lyddiatt A, O'Leary G, Prince M, Stacey D, Wale J, Welch V, Wilson AJ, Tugwell PS. Responsiveness of the Effective Consumer Scale (EC-17). J Rheumatol. 2009 Sep;36(9):2087-91. doi: 10.3899/jrheum.090363. PubMed PMID: 19738218. 16: Kirwan JR, Newman S, Tugwell PS, Wells GA, Hewlett S, Idzera L, Laslo B, March LM, Minnock P, Montie P, Nicklin J, Rader T, Richards P, Sanderson TC, Suarez-Almazor M, Tanjong-Ghogomu E, Ueffing E, Welch V. Progress on incorporating the patient perspective in outcome assessment in rheumatology and the emergence of life impact measures at OMERACT 9. J Rheumatol. 2009 Sep;36(9):2071-6. doi: 10.3899/jrheum.090360. PubMed PMID: 19738216. 17: Konecny GE, Santos L, Winterhoff B, Hatmal M, Keeney GL, Mariani A, Jones M, Neuper C, Thomas B, Muderspach L, Riehle D, Wang HJ, Dowdy S, Podratz KC, Press MF. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer. 2009 Jan 13;100(1):89-95. doi: 10.1038/sj.bjc.6604814. Epub 2008 Dec 16. PubMed PMID: 19088718; PubMed Central PMCID: PMC2634683. 18: Tomillero A, Moral MA. Gateways to clinical trials. July-August 2008. Methods Find Exp Clin Pharmacol. 2008 Jul-Aug;30(6):459-95. PubMed PMID: 18850047. 19: Suwannaprapha P, Chaisri U, Riyong D, Maneerat Y. Improvement of function and morphology of tumor necrosis factor-alpha treated endothelial cells with 17-beta estradiol: a preliminary study for a feasible simple model for atherosclerosis. Circ J. 2005 Jun;69(6):730-8. PubMed PMID: 15914954. 20: Berstein L, Zimarina T, Kovalevskij A, Maximov S, Volkov O, Thijssen JH. CYP19 gene expression and aromatase activity in endometrial cancer tissue: importance of the type of the disease. Neoplasma. 2005;52(2):115-8. PubMed PMID: 15800709.